Your browser doesn't support javascript.
loading
Phase I/II Trial of Dose-Escalated Busulfan Delivered by Prolonged Continuous Infusion in Allogeneic Transplant Patients.
Shea, Thomas C; Walko, Christine; Chung, Yunro; Ivanova, Anastasia; Sheets, Julia; Rao, Kamakshi; Gabriel, Don; Comeau, Terry; Wood, William; Coghill, James; Armistead, Paul; Sarantopoulos, Stefanie; Serody, Jonathan.
  • Shea TC; Program in Bone Marrow and Stem Cell Transplantation, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina; University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina. Electronic address: sheat@med.unc.edu.
  • Walko C; DeBartolo Family Personalized Medicine Institute, Division of Population Science, Moffitt Cancer Center, Tampa, Florida.
  • Chung Y; Department of Biostatistics, University of North Carolina School of Public Health, Chapel Hill, North Carolina.
  • Ivanova A; University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina; Department of Biostatistics, University of North Carolina School of Public Health, Chapel Hill, North Carolina.
  • Sheets J; Program in Bone Marrow and Stem Cell Transplantation, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.
  • Rao K; Program in Bone Marrow and Stem Cell Transplantation, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.
  • Gabriel D; Program in Bone Marrow and Stem Cell Transplantation, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina; University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina.
  • Comeau T; Stem Cell Transplant Program, St. John's Regional Hospital, New Brunswick, Canada.
  • Wood W; Program in Bone Marrow and Stem Cell Transplantation, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina; University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina.
  • Coghill J; Program in Bone Marrow and Stem Cell Transplantation, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina; University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina.
  • Armistead P; Program in Bone Marrow and Stem Cell Transplantation, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina; University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina.
  • Sarantopoulos S; Division of Cellular Therapy, Duke University, Durham, North Carolina.
  • Serody J; Program in Bone Marrow and Stem Cell Transplantation, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina; University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina.
Biol Blood Marrow Transplant ; 21(12): 2129-2135, 2015 Dec.
Article en En | MEDLINE | ID: mdl-26210442
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Vidarabina / Busulfano / Trasplante de Células Madre Hematopoyéticas / Neoplasias Hematológicas / Acondicionamiento Pretrasplante / Agonistas Mieloablativos Tipo de estudio: Clinical_trials / Observational_studies / Prognostic_studies Límite: Adult / Female / Humans / Male / Middle aged Idioma: En Año: 2015 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Vidarabina / Busulfano / Trasplante de Células Madre Hematopoyéticas / Neoplasias Hematológicas / Acondicionamiento Pretrasplante / Agonistas Mieloablativos Tipo de estudio: Clinical_trials / Observational_studies / Prognostic_studies Límite: Adult / Female / Humans / Male / Middle aged Idioma: En Año: 2015 Tipo del documento: Article